Host-defence caerin 1.1 and 1.9 peptides suppress B16 melanoma growth by inducing apoptosis and disrupting lipid metabolism - 20/07/25
, Tianfang Wang e, f, ⁎
, Guoying Ni a, b, d, ⁎ 
Abstract |
Caerin peptides, originally isolated from the skin secretions of Australian tree frogs of the genus Litoria, have shown potential as anti-cancer agents in previous studies. This study investigates the impact of caerin 1.1 and 1.9 (F1/F3) peptides on lipid and amino acid metabolism in B16 melanoma cells, assessing their effects on cell proliferation and the tumour microenvironment (TME). F1/F3 significantly inhibited the proliferation of B16 cells in vitro, and metabolomic analysis revealed lipid metabolites, including lysophosphatidylcholines, phosphatidylcholines, phosphatidylethanolamines, and polyunsaturated fatty acids, were significantly downregulated in vivo in a murine model. Pathway enrichment analysis further highlighted suppressed fatty acid biosynthesis and unsaturated fatty acid synthesis, suggesting an impairment in lipid metabolic processes. Additionally, elevated levels of proinflammatory cytokine expression and inflammatory macrophage infiltration were observed in the TME, likely contributing to the enhanced anti-tumour response. Branched-chain amino acid degradation pathways were also less active in the F1/F3 group, suggesting altered acetyl-CoA availability impacting lipid synthesis. Notably, metabolites such as 3-Hydroxyvalproic acid and carnitine derivatives were markedly elevated, indicating potential antiproliferative and anti-inflammatory effects. These findings suggest that caerin peptides exert anti-cancer effects through multifaceted mechanisms, including modulation of lipid metabolism and immune activation, positioning caerin peptides as promising candidates for combination therapy in melanoma and potentially other malignancies.
El texto completo de este artículo está disponible en PDF.Graphical Abstract |
Highlights |
• | Caerin 1.1 and 1.9 peptides inhibit melanoma growth and prolong survival in B16 tumour-bearing mice. |
• | Caerin 1.1/1.9 disrupts lipid metabolism by downregulating FASN, ACC2, SREBP-1, and NPC2. |
• | Caerin 1.1/1.9 induces apoptosis through cytochrome C and AMPK activation while inhibiting VEGF, EGFR, and NFκB pathways. |
Keywords : Melanoma, B16 cell, Caerin peptide, Lipid metabolism, Metabolomics
Esquema
Vol 189
Artículo 118242- août 2025 Regresar al númeroBienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
¿Ya suscrito a @@106933@@ revista ?
